Generic placeholder image

Current Pharmaceutical Design


ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Connecting the Brain and New Drug Targets for Schizophrenia

Author(s): H. C. Whalley, J. D. Steele, P. Mukherjee, L. Romaniuk, A. M. McIntosh, J. Hall and S. M. Lawrie

Volume 15, Issue 22, 2009

Page: [2615 - 2631] Pages: 17

DOI: 10.2174/138161209788957500

Price: $65


One thing we know for certain after decades of functional imaging in schizophrenia is that it is not a disorder that can simply be attributed to circumscribed lesions in the brain. It is, in other words, a disorder of the connectivity of the brain. In this overview, we will consider the power of connectivity analyses of functional MRI (and PET) data as tools for translational neuroscience. We describe the patterns of functional and effective disconnectivity seen in schizophrenia and particular psychotic symptoms, those that appear to be attributable to genetic and/or environmental risk factors for psychosis, the potential of these disconnectivities as trait and state biomarkers, and their sensitivity to drug effects. We conclude that substantial work needs to be done on standardising connectivity analyses across laboratories and that disconnectivity studies should be an integral part of drug discovery programmes.

Keywords: Connectivity, fMRI, schizophrenia

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy